AYUMI Pharmaceutical Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
363
- Latest Deal Type
-
Buyout/LBO
- (Cancelled)
- Financing Rounds
-
4
AYUMI Pharmaceutical General Information
Description
Manufacturer of specialty pharmaceuticals based in Tokyo, Japan. The company offers a portfolio of drug products addressing anti-rheumatism and orthopedic pain management through an expert team of doctors, enabling patients to get a cure for their disease and stay healthy.
Contact Information
Website
www.ayumi-pharma.comCorporate Office
- Kabukiza Tower 19 Floor
- 4-12-15 Ginza, Chuo-ku
- Tokyo, 104-0061
- Japan
Corporate Office
- Kabukiza Tower 19 Floor
- 4-12-15 Ginza, Chuo-ku
- Tokyo, 104-0061
- Japan
AYUMI Pharmaceutical Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
AYUMI Pharmaceutical Comparisons
Industry
Financing
Details
AYUMI Pharmaceutical Competitors (16)
One of AYUMI Pharmaceutical’s 16 competitors is Eli Lilly and Company, a Corporation company based in Indianapolis, IN.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Eli Lilly and Company | Corporation | Indianapolis, IN | ||||
Merck & Co. | Corporation | Rahway, NJ | ||||
Brii Biosciences | Formerly VC-backed | Beijing, China | ||||
Catalyst Pharmaceuticals | Corporation | Coral Gables, FL | ||||
Genentech | Formerly VC-backed | South San Francisco, CA |
AYUMI Pharmaceutical Patents
AYUMI Pharmaceutical Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20230255907-A1 | Tablet and method for manufacturing same | Pending | 03-Jul-2020 | ||
JP-7360460-B2 | Orally disintegrating tablet and its manufacturing method | Active | 07-Jun-2019 | ||
EP-3981432-A4 | Therapeutic agent for wolfram syndrome | Active | 27-Mar-2019 | ||
EP-3981432-A1 | Therapeutic agent for wolfram syndrome | Active | 27-Mar-2019 | ||
JP-7494163-B2 | Treatment for wolfram syndrome | Active | 27-Mar-2019 | A61P3/10 |
AYUMI Pharmaceutical Signals
AYUMI Pharmaceutical Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
AYUMI Pharmaceutical FAQs
-
When was AYUMI Pharmaceutical founded?
AYUMI Pharmaceutical was founded in 2015.
-
Where is AYUMI Pharmaceutical headquartered?
AYUMI Pharmaceutical is headquartered in Tokyo, Japan.
-
What is the size of AYUMI Pharmaceutical?
AYUMI Pharmaceutical has 363 total employees.
-
What industry is AYUMI Pharmaceutical in?
AYUMI Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is AYUMI Pharmaceutical a private or public company?
AYUMI Pharmaceutical is a Private company.
-
What is the current valuation of AYUMI Pharmaceutical?
The current valuation of AYUMI Pharmaceutical is
. -
What is AYUMI Pharmaceutical’s current revenue?
The current revenue for AYUMI Pharmaceutical is
. -
Who are AYUMI Pharmaceutical’s investors?
Hisamitsu Pharmaceutical, Toho Holdings, and Blackstone have invested in AYUMI Pharmaceutical.
-
Who are AYUMI Pharmaceutical’s competitors?
Eli Lilly and Company, Merck & Co., Brii Biosciences, Catalyst Pharmaceuticals, and Genentech are some of the 16 competitors of AYUMI Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »